Tesamorelin, commonly known by the brand name Egrifta, is a synthetic growth hormone-releasing hormone (GHRH) analogue approved by the FDA strictly for subcutaneous injection to reduce abdominal fat in HIV-infected patients. While related peptides like sermorelin exist in intranasal forms, FDA-approved tesamorelin is administered via daily abdominal injections.
